missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. 30170899

Siglec-2/CD22 Antibody (inotuzumab-CLM) [Janelia Fluor™ 525], Novus Biologicals™

Human Monoclonal Antibody

Brand:  Novus Biologicals (Bio-Techne) NBP3-28483JF525

3217.25 NOK valid until 2025-12-16
BEST PRICE on Promo! Use promo code "24090" to get your promotional price.

Product Code. 30170899

  • 3790.00 NOK / 0.10mL

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

Siglec-2/CD22 Monoclonal antibody specifically detects Siglec-2/CD22 in Human samples. It is validated for Flow Cytometry,ELISA,Functional Assay
TRUSTED_SUSTAINABILITY
Specifications

Specifications

Siglec-2/CD22
Monoclonal
Janelia Fluor 525
B-cell receptor CD22, BL-CAM, B-lymphocyte cell adhesion molecule, CD22 antigenMGC130020, CD22 molecule, sialic acid binding Ig-like lectin 2, Sialic acid-binding Ig-like lectin 2, SIGLEC-2, SIGLEC2FLJ22814, T-cell surface antigen Leu-14
Siglec-2/ CD22
0.1 mL
Adaptive Immunity, B Cell Development and Differentiation Markers, DNA Repair, Immunology, Phospho Specific
933
Store at 4°C in the dark.
IgG1
Flow Cytometry, ELISA, Functional Assay
inotuzumab-CLM
50mM Sodium Borate
Human
Protein A purified
RUO
Primary
Human
Purified
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.